Utilizing its proprietary DNA writing technology to create oligo pools, genes, and synthetic libraries, Twist Biopharma, a division of Twist Bioscience, provides the biotechnology industry with an end-to-end antibody discovery solution. This solution includes (1) a panel of high diversity synthetic antibody libraries, (2) a proprietary human anti-GPCR antibody phage display library focused on this validated target class, and (3) a Twist Antibody Optimization (TAO) platform for antibody affinity and developability. In this webinar, he will discuss:
- Twist Biopharma's proprietary DNA writing technology
- Approaches for creating synthetic DNA libraries for phage display-based discovery
Aaron Sato, CSO, Twist Biopharma
LakPharma Webinar 2019
Comments
Post a Comment